PODDTIPS: Flot.Bio möter Gunilla Osswald

Philip from Flot.Bio was at BIO-Europe in Stockholm in November, talking with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer’s.

In 2023, BioArctic brought the first disease-modifying drug for Alzheimer’s disease to the US market, in partnership with Eisai and Biogen.

Since the recording, Leqembi is now also approved in the European Union 🇪🇺👏

“We are pioneering with a completely new kind of treatment.”

We talked about the science and business behind Leqembi.

“I think the beauty of what BioArctic is doing is the Swedish mutation and then the Arctic mutation of Alzheimer’s disease.”

We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech.

You can watch (or listen) to the episode for free on YouTube, Spotify or Apple.

Philip and Flot.Bio: Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots: https://bit.ly/4gnTNsn